Laura Bukavina, Urologic Oncologist at Cleveland Clinic Urology, shared a post on X about a recent paper by Cagri Akpinar et al. published in International Journal of Urology:

“Variant histology in bladder cancer poses a unique treatment challenge. A study of 221 patients found no survival benefit from NAC.

No significant differences in outcomes (OS: HR 1.88, p=0.14; CSS: HR 1.34, p=0.50; RFS: HR 1.13). Use NAC cautiously in VH, as response may hinge on the % of urothelial component.”

“The effect of neoadjuvant chemotherapy on survival outcomes in patients with variant histologies who underwent radical cystectomy with precystectomy diagnostic accuracy: A multicenter study of the Turkish Urooncology Association”

Authors: Cagri Akpinar, Evren Suer, Bülent Akdogan, Volkan Izol, Serdar Celik, Guven Aslan, Hacı Murat Akgul, Deniz Bolat, Sinan Sozen, Mutlu Deger, Sumer Baltaci.

Laura Bukavina: A study of 221 patients found no survival benefit from NAC in bladder cancer

More posts featuring Laura Bukavina.